Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $231.56 million. The enterprise value is $57.19 million.
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 56.20 million shares outstanding. The number of shares has increased by 68.53% in one year.
| Current Share Class | 56.20M |
| Shares Outstanding | 56.20M |
| Shares Change (YoY) | +68.53% |
| Shares Change (QoQ) | +24.97% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 72.61% |
| Float | 49.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.69, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.69 |
| Quick Ratio | 15.39 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.27% and return on invested capital (ROIC) is -25.24%.
| Return on Equity (ROE) | -37.27% |
| Return on Assets (ROA) | -24.29% |
| Return on Invested Capital (ROIC) | -25.24% |
| Return on Capital Employed (ROCE) | -38.28% |
| Weighted Average Cost of Capital (WACC) | 12.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.38M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.56% in the last 52 weeks. The beta is 1.45, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | +42.56% |
| 50-Day Moving Average | 4.71 |
| 200-Day Moving Average | 5.29 |
| Relative Strength Index (RSI) | 45.56 |
| Average Volume (20 Days) | 679,461 |
Short Selling Information
The latest short interest is 5.89 million, so 10.48% of the outstanding shares have been sold short.
| Short Interest | 5.89M |
| Short Previous Month | 3.74M |
| Short % of Shares Out | 10.48% |
| Short % of Float | 11.90% |
| Short Ratio (days to cover) | 7.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.05M |
| Pretax Income | -63.31M |
| Net Income | -63.31M |
| EBITDA | -69.69M |
| EBIT | -70.05M |
| Earnings Per Share (EPS) | -$1.35 |
Full Income Statement Balance Sheet
The company has $135.79 million in cash and $3.06 million in debt, giving a net cash position of $174.37 million or $3.10 per share.
| Cash & Cash Equivalents | 135.79M |
| Total Debt | 3.06M |
| Net Cash | 174.37M |
| Net Cash Per Share | $3.10 |
| Equity (Book Value) | 181.21M |
| Book Value Per Share | 3.29 |
| Working Capital | 131.08M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$63.00 million and capital expenditures -$50,000, giving a free cash flow of -$63.05 million.
| Operating Cash Flow | -63.00M |
| Capital Expenditures | -50,000 |
| Depreciation & Amortization | 369,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -63.05M |
| FCF Per Share | -$1.12 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |